First Announced Upper GI Patient Procedure for Motus GI’s Pure-Vu EVS Gastro, post FDA Clearance

November 10, 2023

DENVER, Colo., Nov 10, 2023 (247marketnews.com)- Motus GI Holdings Inc (NASDAQ:MOTS) reported, this morning, that its Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance, performed by Dr. Brian Hanson, Gastroenterologist and Associate Professor of Medicine, University of Minnesota.

Motus GI Holdings Inc is trading at $4.03, up $0.49 (+13.84%) on 1.95M premarket shares.

Its 52-week range is $3.33 to $28.80. It set a new 52-week low yesterday, so it may catch some shorts on this rebound.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.